Exclusive Summary

• This diazepam nasal spray has US FDA certification and registration, meeting USP standards, demonstrating its global quality and compliance.
• As a rapid intervention for acute epileptic seizures, especially in out-of-hospital settings, it fills a gap in existing treatment models.
• The product addresses a significant unmet need and penetration potential in the critical out-of-hospital epilepsy emergency market.
• Compared to other dosage forms, nasal spray administration offers clinical advantages of rapid onset and ease of use.
• Although a generic drug, its US-FDA GMP and registration status provide significant market access and competitive advantages.